Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
721 Clinic Dr
Ste A
Tyler, TX 75701Phone+1 903-592-6152Fax+1 903-526-0629
Education & Training
Baylor College of MedicineFellowship, Hematology, 1985 - 1987- Baylor College of MedicineResidency, Internal Medicine, 1981 - 1984
- Baylor College of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1981 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- TR(ACE) Assay Clinical Specimen Study Start of enrollment: 2016 Sep 01
- Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Publications & Presentations
PubMed
- 3 citationsEganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, ...Brenda C O'Connell, Charley Hubbard, Nora Zizlsperger, Donna Fitzgerald, Jeffrey L Kutok
Journal for Immunotherapy of Cancer. 2024-08-30 - 4 citationsA multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE).Sharmeen Mahmood, Daneng Li, Arielle Lee, Julie Rowe, Muhammed Beg
Future Oncology. 2022-12-01 - 5 citationsTwo-Year Tumor Outcomes of a Phase 2B, Randomized, Double-Blind Trial of Avasopasem Manganese (GC4419) Versus Placebo to Reduce Severe Oral Mucositis Owing to Concurre...Carryn M Anderson, Christopher M Lee, Deborah Saunders, Amarinthia E Curtis, Neal E Dunlap
International Journal of Radiation Oncology, Biology, Physics. 2022-11-01
Press Mentions
- Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast CancerJanuary 22nd, 2021
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
